Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs ...

Doctors Without Borders (MSF) and organisations representing people with diabetes picketed outside the offices of insulin ...

Novo Nordisk is conducting a large-scale clinical trial for Alzheimer’s disease, an area of research fraught with challenges.

Doctors Without Borders (MSF) has pinned the blame for South Africa’s current insulin pen shortage on Novo Nordisk. The ...

Doctors Without Borders, also known as Médecins Sans Frontières (MSF), and organisations representing people with diabetes ...

UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The company’s shares ... In comparison, last year the company ...

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden ...

The good news is that HHS recognizes that vitally important anti-obesity medicines like Wegovy and Zepbound should be made available to all Americans, regardless of income. The bad news is that unless ...